Your browser doesn't support javascript.
loading
The feasibility and outcomes of metabolic and bariatric surgery prior to neoplastic therapy.
Parmar, Chetan; Abi Mosleh, Kamal; Aeschbacher, Pauline; Halfdanarson, Thorvardur R; McKenzie, Travis J; Rosenthal, Raul J; Ghanem, Omar M.
Afiliação
  • Parmar C; Department of Surgery, Whittington Hospital, London, UK; University College London, London, UK.
  • Abi Mosleh K; Department of Surgery, Mayo Clinic, Rochester, Minnesota.
  • Aeschbacher P; Department of General Surgery and Bariatric and Metabolic Institute, Cleveland Clinic Florida, Weston, Florida.
  • Halfdanarson TR; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
  • McKenzie TJ; Department of Surgery, Mayo Clinic, Rochester, Minnesota.
  • Rosenthal RJ; Department of General Surgery, Bariatric and Metabolic Institute, Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida.
  • Ghanem OM; Department of Surgery, Mayo Clinic, Rochester, Minnesota. Electronic address: Ghanem.omar@mayo.edu.
Surg Obes Relat Dis ; 20(8): 717-728, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38594091
ABSTRACT

BACKGROUND:

Metabolic and bariatric surgery (MBS) is a potent intervention for addressing obesity-related medical conditions and achieving sustainable weight loss. Beyond its conventional role, MBS has demonstrated potential to serve as a transitional step for patients requiring various interventions. However, the implications of MBS in the context of neoplasia remain understudied.

OBJECTIVES:

To explore the feasibility of MBS as a possible attempt to reduce surgical and treatment risks in patients with benign tumors or low-grade cancers.

SETTING:

Multicenter review from twelve tertiary referral centers spanning 8 countries.

METHODS:

A retrospective review of patients with a diagnosis of primary neoplasia, deemed inoperable or high-risk due to obesity, and receiving primary MBS prior to neoplastic therapy. Data encompassed baseline characteristics, neoplasia characteristics, MBS outcomes, and neoplastic therapy outcomes.

RESULTS:

Thirty-seven patients (median age 52 years, 75.7% female, median BMI of 49.1 kg/m2) were included. There were 9 distinct organs of origin of primary neoplasia, with the endometrium (43.2%) being the most common, followed by the pancreas, colon, kidney and breast. Sleeve gastrectomy (SG) was the most commonly performed MBS procedure (78.4%), with no MBS-related complications or mortalities reported over an average of 4.3 ± 3.9 years. Thirty-one patients (83.8%) eventually underwent neoplastic surgery, with a mean BMI decrease from 49.9 kg/m2 to 39.7 kg/m2 at surgery over an average of 5.8 ± 4.8 months. There were 2 (6.7%) documented mortalities associated with neoplastic surgical intervention.

CONCLUSIONS:

This study highlights the potential feasibility of employing MBS prior to neoplastic therapy in patients with low-grade, less aggressive neoplasms in the context of obesity. This underscores the importance of providing a personalized, case-to-case multidisciplinary approach in the management of these patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estudos de Viabilidade / Cirurgia Bariátrica / Neoplasias Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Surg Obes Relat Dis Assunto da revista: METABOLISMO Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estudos de Viabilidade / Cirurgia Bariátrica / Neoplasias Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Surg Obes Relat Dis Assunto da revista: METABOLISMO Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido